

**Freedom of Information Act 2000 - Request Reference Fol/20/090**

**Anti-infectives**

**Request details**

I have a Freedom of Information request that I hope you'll be able to help me with, it is with regards to the use of Anti Infectives within your Organisation:

- 1. How many patients have you treated in the last 12 months for complicated Intra Abdominal Infections with the following:**

Drug Name	Total
Amoxicillin/clauvanate	
Piperacillin/tazobactam	
Ceftazidime/avibactam (Zavicefta)	
Ceftolozane/tazobactam (Zerbaxa)	
Carbapenems (such as: Meropenem, Imipenem/cilastatin, Ertapenem)	
Aminoglycosides (such as: Gentamicin, Amikacin, Tobramycin)	
Cephalosporins (such as: Cefotaxime, Ceftazidime, Ceftriaxone)	
Quinolones (such as: Ciprofloxacin, Levofloxacin, Ofloxacin)	
Polymixins (such as: Colistin)	

- 2. How many patients have you treated in the last 12 months for Complicated Urinary Tract Infections with the following:**

Drug Name	Total
Amoxicillin/clauvanate	
Piperacillin/tazobactam	
Ceftazidime/avibactam (Zavicefta)	
Ceftolozane/tazobactam (Zerbaxa)	
Carbapenems (such as: Meropenem, Imipenem/cilastatin, Ertapenem)	
Aminoglycosides (such as: Gentamicin, Amikacin, Tobramycin)	
Cephalosporins (such as: Cefotaxime, Ceftazidime, Ceftriaxone)	
Quinolones (such as: Ciprofloxacin, Levofloxacin, Ofloxacin)	
Polymixins (such as: Colistin)	

**3. How many patients have you treated in the last 12 months for hospital acquired Pneumonia and / or Ventilator acquired Pneumonia (HAP/VAP) with the following**

Drug Name	Total
Amoxicillin/clauvanate	
Piperacillin/tazobactam	
Ceftazidime/avibactam (Zavicefta)	
Ceftolozane/tazobactam (Zerbaxa)	
Carbapenems (such as: Meropenem, Imipenem/cilastatin, Ertapenem)	
Aminoglycosides (such as: Gentamicin, Amikacin, Tobramycin)	
Cephalosporins (such as: Cefotaxime, Ceftazidime, Ceftriaxone)	
Quinolones (such as: Ciprofloxacin, Levofloxacin, Ofloxacin)	
Polymixins (such as: Colistin)	

**Response details**

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

Under our Section 16 obligation, the duty to provide advice and assistance, the UHB would like to advise that we have point of prevalence data that is collected on a single day a year. The 2018 PPS report is published on the HARP website at;

<https://phw.nhs.wales/services-and-teams/harp/antimicrobial-resistance-and-prescribing-surveillance-and-reports/>